Tagrisso manufacturer?

Tagrisso (osimertinib) is a brand‑name medication developed and manufactured by AstraZeneca.
- Manufacturer: AstraZeneca (UK‑based multinational pharmaceutical company)
- Key details:
- Approved for first‑line and second‑line treatment of metastatic non‑small‑cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R point mutations.
- Also approved for the treatment of metastatic NSCLC with an EGFR T790M mutation after resistance to an EGFR tyrosine‑kinase inhibitor.
- Available in several countries worldwide; in the U.S. it is sold under the brand name Tagrisso by AstraZeneca’s U.S. subsidiary.

If you need more specifics—such as dosing, formulation, or clinical data—just let me know!